Morphic Holding Inc

Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Morphic Holding, Inc., operates as a biopharmaceutical company, which researches and develops oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.

Morphic Holding, Inc. (MORF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Morphic Holding, Inc. (MORF) Q1 Earnings Expected to Decline

This experimental biotech has more than tripled investors' money over the past 12 months.

Is Morphic Holding a Buy?

The shares of Morphic Holding Inc (NASDAQ: MORF) have received a price target increase from $40 to $103 by Wells Fargo.  These are the details.

MORF Stock Price: $103 Target (Up From $40) By Wells Fargo

WALTHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the pricing of an upsized underwritten public offering of 3,500,000 shares of its common stock at a price to the public of $70.00 per share. The gross proceeds from this offering are expected to be approximately $245.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Morphic. The offering is expected to close on or about March 5, 2021, subject to the satisfaction of customary closing conditions. Morphic has also granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock in connection with the public offering. All of the shares of common stock are being offered by Morphic.

Morphic Therapeutic Announces Pricing of Upsized $245.0 Million Public Offering

The company announced a proposed public offering of common stock.

Why Morphic Holding Stock Is Falling Today

Morphic Holding, Inc. (MORF) CEO Praveen Tipirneni on Q4 2020 Results - Earnings Call Transcript

A series of positive news is helping the biopharmaceutical company start the week on a strong note.

Why Morphic Holding Stock Is Skyrocketing Today

Athenex

Lixte Biotech

Morphic Holding Inc (NASDAQ: MORF), Athenex Inc (NASDAQ: ATNX) and Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) are among the healthcare movers on Monday. Morphic Jumps On Data: Morphic, a biopharma developing oral integrin therapies for treating chronic diseases, reported positive Phase 1 data for its MORF-057, which is being evaluated for inflammatory bowel disease.

Why Morphic, Athenex, Lixte Biotech Are Moving Today

Little-known MORF stock is rocketing higher after Morphic Holdings shared positive interim data from a Phase 1 clinical trial. The post MORF Stock: Why Little-Known Morphic Holdings Is Up 100% Today appeared first on InvestorPlace.

MORF Stock: Why Little-Known Morphic Holdings Is Up 100% Today

The stock price of Morphic Holding Inc (NASDAQ: MORF) has increased by over 100% during intraday trading as of 11 AM ET. This is why it happened.

MORF Stock Price Increases Over 100% Intraday: Why It Happened

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -54.05% and -26.24%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Morphic Holding, Inc. (MORF) Reports Q4 Loss, Misses Revenue Estimates

MORF-057 well tolerated in all dose cohorts

Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057

Announced positive preliminary results from Phase 1 SAD clinical trial of MORF-057

Morphic Announces Corporate Highlights and Financial Results for the Full Year 2020

Call to discuss financial and operational results for fiscal year 2020 and MORF-057 interim data from SAD portion of ongoing MORF-057 Phase 1 clinical trial Call to discuss financial and operational results for fiscal year 2020 and MORF-057 interim data from SAD portion of ongoing MORF-057 Phase 1 clinical trial

Morphic Therapeutic to Host Analyst and Investor Call on March 1, 2021

Will Morphic Holding, Inc. (MORF) Report Negative Q4 Earnings? What You Should Know

WALTHAM, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer of Morphic Therapeutic, is scheduled to participate in a panel discussion on the gastrointestinal microbiome at the 41st Annual Cowen Health Care Conference. The panel discussion will take place at 11:10 AM ET on Tuesday, March 2, 2021.

Morphic Therapeutic to Participate in GI/Microbiome Panel Discussion at the 41st Annual Cowen Health Care Conference

New program demonstrates breadth of MInT platform with the inclusion of activating antibodies against integrin targets New program demonstrates breadth of MInT platform with the inclusion of activating antibodies against integrin targets

Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program

Olema Pharmaceuticals

Schrodinger 

The biotechnology exchange-traded fund SPDR S&P Biotech ETF (NYSE: XBI) is up around 50% in 2020 and Jefferies' managing director Michael Yee says the valuations are not only justified but sustainable in 2021. ‘Exciting stories' for 2021 While looking at the Biotech sector, it is important to separate the small group of COVID-19 vaccine makers from the overall biotech innovation thesis, Yee said Tuesday on CNBC's “Closing Bell.

Analyst talks Biotech sector, offers three picks for 2021

WALTHAM, Mass., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced that Praveen Tipirneni, M.D., president and chief executive officer, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 4:30 PM ET.

Morphic Therapeutic to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference

As of late, it has definitely been a great time to be an investor in Morphic Holding (MORF).

Morphic Holding's (MORF) Shares March Higher, Can It Continue?

WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that members of the Morphic management are scheduled to participate in the Jefferies Virtual London Healthcare Conference with a Company presentation at 2:55 PM ET on Wednesday, November 18, 2020.

Morphic Therapeutic to Present at the Jefferies Virtual London Healthcare Conference

Initiated p hase 1 clinical trial for MORF-057 with results expected by mid-2021

Morphic Announces Corporate Highlights and Third Quarter 2020 Financial Results

- Data validat e physiologically relevant assay used in MORF-057 Phase 1 studies to measure receptor occupancy of α 4 β 7 integrin - -MORF-057, inhibitor of α 4 β 7 integrin, in development to treat inflammatory bowel disease-

Morphic Announces Presentation of New Data Supporting Development of MORF-057 at UEG Week Virtual 2020

First o rally available  integrin  inhibitor  from MInT Platform to enter the clinic  MORF-057, inhibitor o f  α  4  β  7   integrin ,  in development  to  treat  i nflammatory bowel disease  Phase 1  program to  assess  safety and pharmacokinetics  of MORF-057 as well as  α  4  β  7   r eceptor  o ccupancy  as  a clinically  rel evant biomarker

Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of MORF-057

WALTHAM, Mass., Sept.  21, 2020  (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced two presentations at the Jefferies Next Generation IBD Therapeutics Virtual Summit. Members of the Morphic management team are scheduled to participate in a panel discussion at 8:45 a.m. ET on Wednesday, September 23, 2020, as well as present a company overview at 1:00 p.m. ET on the same day.

News for Morphic Holding Inc Stock (MORF)